Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
about
Targeted Radionuclide Therapy of Human TumorsTherapeutic radionuclides in nuclear medicine: current and future prospectsTumor immunotargeting using innovative radionuclidesDevelopment of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results.Two-stage hepatectomy (R0) with portal vein ligation--towards curing patients with extended bilobular colorectal liver metastases.The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic ApproachesMultimodal treatment options for bilobar colorectal liver metastasesSystemic radiotherapy can cure lymphoma: a paradigm for other malignancies?Novel radiolabeled antibody conjugates.Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors.Cancer radioimmunotherapy.Radiolabelled monoclonal antibodies in the treatment of metastatic cancerCancer Imaging and Therapy with Bispecific Antibody Pretargeting.Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsTailoring antibodies for radionuclide delivery.Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.Review of clinical radioimmunotherapy.The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis.Improvement of radioimmunotherapy using pretargeting.Comparison between Three Promising ß-emitting Radionuclides, (67)Cu, (47)Sc and (161)Tb, with Emphasis on Doses Delivered to Minimal Residual Disease.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Emerging trends for radioimmunotherapy in solid tumorsHumanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.Radioactive antibodies: a historical review of selective targeting and treatment of cancer.Radioimmunotherapy of solid tumors: searching for the right target.Radioimmunotherapy of non-Hodgkin's lymphoma: from the 'magic bullets' to 'radioactive magic bullets'.Using antibodies to target cancer therapeutics.General overview of radioimmunotherapy of solid tumors.Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy?Antibody-mediated delivery of therapeutics for cancer therapy.α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.In vitro and in vivo anticancer efficacy of unconjugated humanized anti-CEA monoclonal antibodies.A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?
P2860
Q26771267-31509F7A-3D41-428E-97CA-15D5196D9922Q26861998-8BB12C74-E885-4659-A07A-D8EFCAC6636EQ28083230-6DE5F653-4D89-46FD-9A01-416AEA9A22CEQ33301860-07F3592A-DB36-433F-A3C5-9967E5E3AD2EQ33379811-AB1BDAED-1041-4AA9-9BF3-F2A1395BFA7EQ33400076-8F46C84F-19D3-4B32-82CE-CBFF7B6C5C8DQ33409137-23683B56-FEB4-49F6-AB19-8D6DC65231D4Q33690475-38CDDA0A-4E97-458F-82E0-E528354827BBQ33735551-5C6F161A-5881-431B-8E43-321EED35F3E4Q34014614-47AC4AAE-EA52-417C-90AB-974E085DC1DBQ34335207-8456CA26-2074-44B1-B4EE-6265404CE560Q34631801-3A6A6B76-FF80-4473-8BFF-694CEE5027E8Q34645408-AD25BDA9-D6F1-4478-BD2D-2DBABD4993B1Q35070045-F19C1E36-837C-48EC-95E7-D88D146D9859Q35840380-4A4DCFC4-DA99-48E1-92FF-AC09798360B9Q36082355-FE340149-0148-4C9E-9EF5-4B8800E5B2EFQ36323585-0D03BD3B-1B4B-4985-9C05-04C472A947D1Q36349687-78F8D343-E96C-493E-BDF8-4BF28D2E02EDQ36391426-2FAB0FDC-895A-4B75-8037-AC1D6FFD8498Q36407480-07C35044-EE69-4CB8-9798-14EA2D5D3FA1Q36903804-C6094438-9FD3-4162-A506-B4FDFE517C95Q36941931-E2462CF8-5875-4F8B-AB8D-008EEAB21050Q37112963-6C3BF9F6-3DF1-4C7E-A235-908927892ED9Q37174938-523B0A90-A0FB-4FBD-8603-94A08B48E31BQ37222795-7C0A5C21-3343-43DD-A281-BB2093A4D93EQ37424092-6CC580BE-8564-4B9D-A39B-51A13AB55F29Q37796519-CAF3888E-0481-4685-BEA6-9C3623FEB5D9Q37804904-88B5DE69-E83D-4FB7-BD53-1EE9B9ADCE1EQ37969746-5C26C50B-7915-4B8E-AF79-63CD6ACEC5CDQ38014920-92F33759-124C-4B10-A552-6B9904597880Q38103579-2B157447-3668-47A4-A3FC-60F04D46D04BQ38230884-AB1ED252-7A5A-414C-964D-C6E0D5148673Q38450531-14F31EC0-9EB3-4711-918E-D87E7E39B711Q38665425-87F14FE6-62EF-489D-9C52-544510434219Q38715106-9B9A3CF4-296E-47E9-AA81-D8A29239408EQ39300912-D6DA1BD4-E181-4C55-B5B4-52688FB0CBAAQ39602064-54AC4C3E-604E-4ED7-86EE-C08C3632D7A0Q42425321-8A5993F0-B373-47FC-B4D3-C11AFC63F283Q42609788-E7FA3F32-B079-43E2-AAFB-E44934FA5CA6Q43764750-2AD52A65-C0AF-4C74-99F4-4FD4B91BEF39
P2860
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Phase II trial of carcinoembry ...... r safety and efficacy results.
@ast
Phase II trial of carcinoembry ...... r safety and efficacy results.
@en
type
label
Phase II trial of carcinoembry ...... r safety and efficacy results.
@ast
Phase II trial of carcinoembry ...... r safety and efficacy results.
@en
prefLabel
Phase II trial of carcinoembry ...... r safety and efficacy results.
@ast
Phase II trial of carcinoembry ...... r safety and efficacy results.
@en
P2093
P356
P1476
Phase II trial of carcinoembry ...... r safety and efficacy results.
@en
P2093
B Michael Ghadimi
Bettina Kulle
Claus Langer
David M Goldenberg
Heinz Becker
Ivan D Horak
Jacqueline Kovacs
Johannes Meller
Peter Markus
Thomas M Behr
P304
P356
10.1200/JCO.2005.18.622
P407
P577
2005-09-01T00:00:00Z